Accelerating vaccine development and introduction
We dare to envision a world where no one dies for want of a vaccine. But vaccines don’t exist for many diseases, and market forces alone are not always enough to drive their development.
PATH accelerates the development and delivery of lifesaving vaccines, as well as the creation of technologies that get vaccines safely to the people who need them. Thanks to a collaborative and integrated approach, we have succeeded in reaching billions of people. But too many children still go unvaccinated, and emerging diseases require new efforts. Our work is far from done.
The Center for Vaccine Innovation and Access
PATH’s Center for Vaccine Innovation and Access brings together PATH’s global expertise across every stage of the long and complex vaccine process, from early discovery and clinical testing of vaccine candidates, to regulatory approval and manufacturing, to introduction and delivery.
PATH’s current vaccine work includes more than two dozen vaccines either in development or already in use to protect against 15 different diseases. By bringing together our expertise, we’re able to respond more quickly to new or rapidly evolving disease threats. We’re also accelerating progress toward preventing—and even eliminating—diseases that have devastated families and kept communities from thriving for far too long.
PATH’s vaccine development efforts focus on the leading causes of children’s deaths worldwide—pneumonia, diarrheal disease, and malaria—as well as other global health priorities, such as polio and meningitis. We work in partnership with national health ministries, pharmaceutical manufacturers, donors, international financing and regulatory organizations, and many others. PATH has led numerous global partnerships, including the award-winning Meningitis Vaccine Project and the Malaria Vaccine Initiative, which helped develop the first malaria vaccine candidate recommended for pilot implementation.
Vaccines need to be transported from manufacturing facilities in temperature-controlled conditions to remote clinics that may have unreliable electricity and refrigeration. PATH develops creative solutions, such as temperature-stable vaccine formulations and solar refrigerators, to ensure vaccines reach the places they are needed most. We also have a long history of developing safe-delivery technologies, including the Soloshot™ syringe, the first commercialized syringe to disable automatically so it cannot be reused.
Finally, PATH works with partners in low-resource settings to ensure that vaccines are accessible to all. We help country decision-makers get the information and resources they need to make informed choices on whether, when, and how to introduce vaccines. We work to build strong, resilient immunization systems that reach even the most remote villages. And we help people understand the value of vaccines, building critical financial, political, and community support.
From a vaccine that prevents the deadliest form of diarrhea to a sticker used on nearly 7 billion vaccine vials to ensure vaccines haven’t been damaged by heat—PATH is making sure that children everywhere get the protection they deserve.
SoloShot is a trademark of BD.
Photo: PATH/Aaron Joel Santos.
Teaming up on a vaccine to protect Vietnam from influenza
Meningitis Vaccine Project
Science, will, and resources create a vaccine to change history
One promising candidate is already in the works